Brain

ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia

MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for...

HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)

The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patientsMUNICH, Germany, June 20, 2023 (GLOBE NEWSWIRE)...

Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease

–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of...

Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches

PURCHASE, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that...

Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

-- Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean...

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

vTv discovered small molecule RAGE inhibitor is being developed by Cantex under worldwide development and commercialization agreementHIGH POINT, N.C., June...

Relievant Medsystems Announces Pooled Three-Year Outcomes from Intracept Procedure that Demonstrate Long-Term Pain Relief and Reduced Opioid Use in Chronic Vertebrogenic Low Back Pain Patients

MINNEAPOLIS, June 15, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

New panel will enable rapid, precise genetic profiling of patients with deadly diseaseNEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE)...

ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target

White paper summarizes the research of leading inflammasome experts, Drs. Helen Bramlett, Juan Pablo de Rivero Vaccari, W. Dalton Dietrich,...

error: Content is protected !!